Abstract
Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by the emergence of multidrug resistance and TB-HIV coinfection. The cumulative knowledge on pharmacokinetics/ pharmacodynamics of antituberculosis agents has recently encouraged therapeutic drug monitoring (TDM) in patient care. However, logistical problems related to conventional sampling limit the application of TDM in research-oriented institutions. Dried blood spot (DBS) compared with conventional venous blood sampling has the advantages of easier sampling, storage and transportation, thus enabling the application of TDM even in remote areas. In addition, DBS with its lower biohazardous risk can be safely performed in a high HIV prevalence area, which also tends to have a high TB burden. Another benefit of DBS sampling is that it requires a smaller blood volume than conventional sampling and is highly recommended for application in pediatric TB. A limitation of DBS is that additional considerations are required for analysis method development and validation. The accuracy of the DBS method is influenced by a number of factors that need to be thoroughly examined in method development and validation. Further, the agreement between DBS and plasma/serum concentrations is not always understood and further investigations are required.
Keywords: Dried blood spot, tuberculosis, optimization, biohazards, malabsorption, rifabutin, isoniazid, ethambutol, hemoglobin, venous plasma
Current Pharmaceutical Design
Title: Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Volume: 17 Issue: 27
Author(s): D. H. Vu, J. W.C. Alffenaar, P. M. Edelbroek, J. R.B.J. Brouwers and D. R.A. Uges
Affiliation:
Keywords: Dried blood spot, tuberculosis, optimization, biohazards, malabsorption, rifabutin, isoniazid, ethambutol, hemoglobin, venous plasma
Abstract: Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by the emergence of multidrug resistance and TB-HIV coinfection. The cumulative knowledge on pharmacokinetics/ pharmacodynamics of antituberculosis agents has recently encouraged therapeutic drug monitoring (TDM) in patient care. However, logistical problems related to conventional sampling limit the application of TDM in research-oriented institutions. Dried blood spot (DBS) compared with conventional venous blood sampling has the advantages of easier sampling, storage and transportation, thus enabling the application of TDM even in remote areas. In addition, DBS with its lower biohazardous risk can be safely performed in a high HIV prevalence area, which also tends to have a high TB burden. Another benefit of DBS sampling is that it requires a smaller blood volume than conventional sampling and is highly recommended for application in pediatric TB. A limitation of DBS is that additional considerations are required for analysis method development and validation. The accuracy of the DBS method is influenced by a number of factors that need to be thoroughly examined in method development and validation. Further, the agreement between DBS and plasma/serum concentrations is not always understood and further investigations are required.
Export Options
About this article
Cite this article as:
H. Vu D., W.C. Alffenaar J., M. Edelbroek P., R.B.J. Brouwers J. and R.A. Uges D., Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470174
DOI https://dx.doi.org/10.2174/138161211797470174 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy AMPA Receptor Potentiators as Novel Antidepressants
Current Pharmaceutical Design Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198
Current Medicinal Chemistry Editorial
Inflammation & Allergy - Drug Targets (Discontinued) Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens
Anti-Infective Agents in Medicinal Chemistry Chemical Constituents from the Chinese Bryophytes and Their Reversal of Fungal Resistance
Current Organic Chemistry An Efficient and Environmentally Benign Access Towards Synthesis of Novel 1,2,3-Triazolyl-pyrazoline Hybrids
Letters in Organic Chemistry Determination of Molecular Properties Effectuating the Growth Inhibition of Mycobacterium Tuberculosis by Various Small Molecule Hydrazides
Letters in Drug Design & Discovery LC-MS/MS Assay for Quantification of a Novel Antitubercular Molecule S006-830: Pharmacokinetic and Plasma Protein Binding Studies in Rats
Current Pharmaceutical Analysis TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7)
Anti-Cancer Agents in Medicinal Chemistry Shikimate Kinase: A Potential Target for Development of Novel Antitubercular Agents
Current Drug Targets Brucellosis Serostatus Among Pregnant Women with Spontaneous Abortion and Stillbirth
Current Women`s Health Reviews Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Preliminary Screening Indicates Promising Antimicrobial Properties of the Stem Bark Extracts of Macaranga rosea
Anti-Infective Agents Roles of L5-7 Loop in the Structure and Chaperone Function of SsHSP14.1
Protein & Peptide Letters The Expanding Universe of γ δ T Lymphocytes: Subsets, Generation and Function
Current Immunology Reviews (Discontinued) Structure-Based Drug Discovery Accelerated by Many-Core Devices
Current Drug Targets The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control
Infectious Disorders - Drug Targets